

Luca Pani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2047060/publications.pdf>

Version: 2024-02-01

181
papers

6,180
citations

71102

41
h-index

82547

72
g-index

187
all docs

187
docs citations

187
times ranked

8784
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. <i>Journal of Internal Medicine</i> , 2014, 275, 251-283.	6.0	540
2	The role of stress in the pathophysiology of the dopaminergic system. <i>Molecular Psychiatry</i> , 2000, 5, 14-21.	7.9	270
3	Nutraceuticals: opening the debate for a regulatory framework. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 659-672.	2.4	246
4	The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. <i>CNS Drugs</i> , 2014, 28, 421-53.	5.9	238
5	Identification of nine tissue-specific transcription factors of the hepatocyte nuclear factor 3/forkhead DNA-binding-domain family. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 3948-3952.	7.1	237
6	Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex. <i>Molecular Psychiatry</i> , 2001, 6, 657-664.	7.9	174
7	Sleep deprivation in the rat: an animal model of mania. <i>European Neuropsychopharmacology</i> , 1995, 5, 89-93.	0.7	156
8	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019, 33, 1039-1057.	4.0	121
9	Identification and validation of biomarkers for autism spectrum disorders. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 70-70.	46.4	117
10	The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. <i>European Journal of Neuroscience</i> , 2001, 13, 409-412.	2.6	101
11	1-(2,4-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. <i>Neurobiology of Disease</i> , 2010, 37, 177-185.	4.4	101
12	Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database. <i>European Heart Journal</i> , 2015, 36, 2454-2462.	2.2	94
13	Calcium receptor antagonists modify cocaine effects in the central nervous system differently. <i>European Journal of Pharmacology</i> , 1990, 190, 217-221.	3.5	92
14	Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marijuana. <i>Molecular Brain Research</i> , 1998, 58, 240-245.	2.3	89
15	Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. <i>Journal of Affective Disorders</i> , 2003, 73, 75-85.	4.1	89
16	Synthesis and Characterization of NESS 0327: A Novel Putative Antagonist of the CB1 Cannabinoid Receptor. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 306, 363-370.	2.5	89
17	The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. <i>European Journal of Neuroscience</i> , 2000, 12, 1123-1127.	2.6	88
18	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 181, 239-244.	1.7	88

#	ARTICLE	IF	CITATIONS
19	High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA). <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 430-437.	3.6	86
20	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 421.	0.8	77
21	The calcium antagonist PN 200-110 inhibits the reinforcing properties of cocaine. <i>Brain Research Bulletin</i> , 1991, 26, 445-447.	3.0	75
22	The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+). <i>Neuroscience Letters</i> , 1990, 117, 129-133.	2.1	73
23	Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. <i>European Journal of Pharmacology</i> , 2003, 459, 97-105.	3.5	72
24	Stress increases noradrenaline release in the rat frontal cortex: Prevention by diazepam. <i>European Journal of Pharmacology</i> , 1990, 176, 229-231.	3.5	69
25	Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia. <i>Psychiatric Services</i> , 2004, 55, 997-1005.	2.0	69
26	Tricyclic Pyrazoles. 4. Synthesis and Biological Evaluation of Analogues of the Robust and Selective CB2Cannabinoid Ligand 1-(2,4-Dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7502-7512.	6.4	68
27	The future is now: Model-based clinical trial design for Alzheimer's disease. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 210-214.	4.7	68
28	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. <i>Molecular Psychiatry</i> , 2022, 27, 1286-1299.	7.9	68
29	Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. <i>European Psychiatry</i> , 2007, 22, 267-275.	0.2	65
30	Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. <i>European Journal of Pharmacology</i> , 1994, 262, 107-111.	3.5	57
31	Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. <i>Psychopharmacology</i> , 2003, 167, 79-84.	3.1	55
32	The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. <i>Molecular Psychiatry</i> , 2002, 7, 247-253.	7.9	54
33	Regulatory evaluation of Glybera in Europe – two committees, one mission. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 719-719.	46.4	54
34	The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. <i>European Journal of Pharmacology</i> , 2004, 504, 61-64.	3.5	51
35	Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 3309-3320.	3.0	51
36	Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden – Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. <i>European Neuropsychopharmacology</i> , 2011, 21, 781-788.	0.7	49

#	ARTICLE	IF	CITATIONS
37	Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system and current environmental conditions in industrialized countries?. <i>Molecular Psychiatry</i> , 2000, 5, 467-475.	7.9	48
38	Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. <i>European Journal of Endocrinology</i> , 2002, 147, 255-261.	3.7	46
39	Rare diseases and effective treatments: are we delivering?. <i>Lancet, The</i> , 2015, 385, 750-752.	13.7	46
40	MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 210-213.	0.5	44
41	Subchronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigrostriatal dopaminergic neurons directly related to "early onset" vacuous chewing. <i>European Journal of Neuroscience</i> , 2002, 15, 1187-1196.	2.6	42
42	Consensus on the Use of Substituted Benzamides in Psychiatric Patients. <i>Neuropsychobiology</i> , 2004, 50, 134-143.	1.9	42
43	The endless frontier? The recent increase of R&D productivity in pharmaceuticals. <i>Journal of Translational Medicine</i> , 2020, 18, 162.	4.4	42
44	Tricyclic Pyrazoles. 3. Synthesis, Biological Evaluation, and Molecular Modeling of Analogues of the Cannabinoid Antagonist 8-Chloro-1-(2,4-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7351-7362.	6.4	39
45	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian ALFA Anti-diabetics Monitoring Registry. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1346-1353.	2.6	39
46	Nimodipine inhibits cocaine-induced dopamine release and motor stimulation. <i>European Journal of Pharmacology</i> , 1990, 176, 245-246.	3.5	37
47	Brain dialysis and dopamine: does the extracellular concentration of dopamine reflect synaptic release?. <i>European Journal of Pharmacology</i> , 1990, 180, 85-90.	3.5	37
48	The R100Q mutation of the GABAA $\alpha 6$ receptor subunit may contribute to voluntary aversion to ethanol in the sNP rat line. <i>Molecular Brain Research</i> , 2001, 87, 263-270.	2.3	37
49	Brain dialysis provides evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex. <i>European Journal of Pharmacology</i> , 1989, 163, 393-395.	3.5	36
50	Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 1921-1933.	3.0	36
51	Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance database. <i>International Journal of Cardiology</i> , 2016, 203, 217-220.	1.7	36
52	Δ^9 -Tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain. <i>European Journal of Neuroscience</i> , 1998, 10, 1743-1751.	2.6	35
53	Effect of Δ^9 -tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: An immunohistochemical study. <i>Brain Research</i> , 2005, 1048, 41-47.	2.2	34
54	Predictors of response to erenumab after 12 months of treatment. <i>Brain and Behavior</i> , 2021, 11, e2260.	2.2	34

#	ARTICLE	IF	CITATIONS
55	Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring rats. <i>Psychopharmacology</i> , 2004, 172, 341-351.	3.1	33
56	Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. <i>Behavioural Brain Research</i> , 2011, 217, 432-438.	2.2	33
57	Correlation between increased AP-1/NGF binding activity and induction of nerve growth factor transcription by multiple signal transduction pathways in C6-2B glioma cells. <i>Molecular Brain Research</i> , 1996, 35, 1-10.	2.3	32
58	Lead intoxication during intrauterine life and lactation but not during adulthood reduces nucleus accumbens dopamine release as studied by brain microdialysis. <i>Toxicology Letters</i> , 2001, 121, 199-206.	0.8	32
59	Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide Report From the Italian Medicines Agency. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 168-172.	2.5	32
60	NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile. <i>Behavioural Brain Research</i> , 2012, 234, 192-204.	2.2	31
61	Haloperidol, but not clozapine, produces dramatic catalepsy in δ^9 -THC-treated rats: possible clinical implications. <i>British Journal of Pharmacology</i> , 2003, 140, 520-526.	5.4	30
62	Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system. <i>Chemistry and Physics of Lipids</i> , 2005, 135, 147-156.	3.2	30
63	An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin. <i>BioDrugs</i> , 2015, 29, 285-300.	4.6	30
64	Cloning and tissue-specific functional characterization of the promoter of the rat diazepam binding inhibitor, a peptide with multiple biological actions.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 8439-8443.	7.1	28
65	Practical Issues with Amisulpride in the Management of Patients with Schizophrenia. <i>Clinical Drug Investigation</i> , 2008, 28, 465-477.	2.2	28
66	Unexplained Somatic Symptoms during Major Depression: Prevalence and Clinical Impact in a National Sample of Italian Psychiatric Outpatients. <i>Psychopathology</i> , 2011, 44, 116-124.	1.5	25
67	Novel Epigenetic Target Therapy for Prostate Cancer: A Preclinical Study. <i>PLoS ONE</i> , 2014, 9, e98101.	2.5	25
68	Reduced TH-immunoreactive fibers in the limbic system of Sardinian alcohol-preferring rats. <i>Brain Research</i> , 2002, 924, 242-251.	2.2	23
69	Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 319-331.	5.0	23
70	Evaluation of Tamsulosin and Alfuzosin Activity in the Rat Vas Deferens: Relevance to Ejaculation Delays. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 710-717.	2.5	22
71	Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus accumbens. <i>Brain Research</i> , 2007, 1141, 15-24.	2.2	22
72	<i>Oct4</i> expression in <i>in vitro</i> produced sheep blastocysts and embryonic stem-like cells. <i>Cell Biology International</i> , 2010, 34, 53-60.	3.0	22

#	ARTICLE	IF	CITATIONS
73	Daptomycin in paediatrics: current knowledge and the need for future research. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 643-648.	3.0	22
74	Chronic imipramine, l-sulpiride and mianserin decrease corticotropin releasing factor levels in the rat brain. <i>Neuroscience Letters</i> , 1995, 192, 121-123.	2.1	21
75	The 5-HT ₂ antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex. <i>Molecular Psychiatry</i> , 2000, 5, 673-677.	7.9	20
76	(α^1)S amisulpride binds with high affinity to cloned dopamine D ₃ and D ₂ receptors. <i>European Journal of Pharmacology</i> , 2001, 432, 143-147.	3.5	20
77	Haloperidol versus risperidone on rat α -early onset β -vacuous chewing. <i>Behavioural Brain Research</i> , 2004, 149, 9-16.	2.2	20
78	Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 730-742.	4.7	20
79	Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. <i>Neurological Sciences</i> , 2021, 42, 4193-4202.	1.9	20
80	Discriminative Hypomania Checklist-32 Factors in Unipolar and Bipolar Major Depressive Patients. <i>Psychopathology</i> , 2012, 45, 390-398.	1.5	18
81	Towards a framework for treatment effectiveness in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1867.	2.2	18
82	Flunarizine potentiates cocaine-induced dopamine release and motor stimulation in rats. <i>European Journal of Pharmacology</i> , 1990, 190, 223-227.	3.5	17
83	Are α -social drugs β -(tobacco, coffee and chocolate) related to the bipolar spectrum?. <i>Journal of Affective Disorders</i> , 2011, 133, 227-233.	4.1	17
84	Subthreshold depression in older subjects: An unmet therapeutic need. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 909-913.	3.3	17
85	Reduced DAT- and DBH-immunostaining in the limbic system of Sardinian alcohol-preferring rats. <i>Brain Research</i> , 2002, 948, 192-202.	2.2	16
86	A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. <i>European Psychiatry</i> , 2010, 25, 92-100.	0.2	16
87	ACTH-induced mitochondrial DBI receptor (MDR) and diazepam binding inhibitor (DBI) expression in adrenals of hypophysectomized rats is not cause-effect related to its immediate steroidogenic action. <i>Life Sciences</i> , 1993, 53, 1137-1147.	4.3	15
88	The Italian post-marketing registries. <i>Pharmaceutical Programming</i> , 2012, 5, 57-60.	0.1	15
89	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	8.1	15
90	Disclosure of grounds of α uropean withdrawn and refused applications: a step forward on regulatory transparency. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1149-1151.	2.4	14

#	ARTICLE	IF	CITATIONS
91	Kounis syndrome due to antibiotics: A global overview from pharmacovigilance databases. <i>International Journal of Cardiology</i> , 2016, 224, 406-411.	1.7	14
92	Inhibition of [3H]dopamine uptake by flunarizine. <i>European Journal of Pharmacology</i> , 1991, 203, 67-69.	3.5	13
93	Effect of the amisulpride isomers on rat catalepsy. <i>European Journal of Pharmacology</i> , 2002, 444, 69-74.	3.5	13
94	Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. <i>Neuropharmacology</i> , 2004, 47, 128-135.	4.1	13
95	The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 221-222.	46.4	13
96	Digital Phenotyping and Dynamic Monitoring of Adolescents Treated for Cancer to Guide Intervention: Embracing a New Era. <i>Frontiers in Oncology</i> , 2021, 11, 673581.	2.8	13
97	Conditioned place preference induced by ethanol in a rat line selected for ethanol preference. <i>Pharmacological Research</i> , 1990, 22, 48.	7.1	12
98	Fluoxetine-induced conditioned place preference: A preliminary study. , 1997, 25, 309-311.		12
99	Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylase-immunostaining alterations induced by haloperidol. <i>European Journal of Pharmacology</i> , 2004, 483, 65-69.	3.5	12
100	Multiplex genotyping of <i>CYP3A4</i> , <i>CYP3A5</i> , <i>CYP2C9</i> and <i>CYP2C19</i> SNPs using MALDI-TOF mass spectrometry. <i>Pharmacogenomics</i> , 2010, 11, 559-571.	1.3	12
101	Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold Hopping. <i>Open Medicinal Chemistry Journal</i> , 2012, 6, 1-14.	2.4	12
102	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data from 10-Year Post-marketing Surveillance. <i>Drug Safety</i> , 2015, 38, 1211-1218.	3.2	12
103	Characterization of wild-type (R100R) and mutated (Q100Q) GABAA $\alpha 6$ subunit in Sardinian alcohol non-preferring rats (sNP). <i>Brain Research</i> , 2003, 967, 98-105.	2.2	11
104	Molecular characterization of new polymorphisms at the $\alpha 2$, $\alpha 1$, $\alpha 3$ GABAA receptor subunit genes associated to a rat nonpreferring ethanol phenotype. <i>Molecular Brain Research</i> , 2003, 110, 289-297.	2.3	11
105	Contrasting effects of diazepam and repeated restraint stress on latent inhibition in mice. <i>Behavioural Brain Research</i> , 2007, 183, 147-155.	2.2	11
106	Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent. <i>Behavioural Pharmacology</i> , 2010, 21, 649-653.	1.7	11
107	Steps forward in regulatory pathways for acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 3-8.	7.1	11
108	Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. <i>Neurological Sciences</i> , 2022, 43, 3823-3830.	1.9	11

#	ARTICLE	IF	CITATIONS
109	Are D1 dopamine receptor agonists potential antidepressants?. <i>Pharmacological Research Communications</i> , 1988, 20, 1121-1122.	0.2	10
110	3-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-6-substituted-3,6-diazabicyclo[3.1.1]heptanes as novel potent dopamine uptake inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 3748-3755.	3.0	10
111	Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 217.	2.2	10
112	The placebo arm in clinical studies for treatment of Psychiatric Disorders: A Regulatory Dilemma. <i>European Neuropsychopharmacology</i> , 2012, 22, 804-811.	0.7	10
113	Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1343-1346.	3.1	10
114	Reflections on Decisions Taken on Well Established Use Medicinal Products by EU Regulators and the ECJ: A Pharmaceutical Regulatory Perspective. <i>Scientia Pharmaceutica</i> , 2014, 82, 655-663.	2.0	10
115	Alternative Pricing Strategies for Cancer Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 857.	7.4	10
116	Adherence to Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Prescriptions Affects Overall Medication Adherence in Older Persons. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1712-1718.	2.2	10
117	Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect. <i>European Journal of Pharmacology</i> , 2002, 447, 109-114.	3.5	9
118	Synthesis and in vitro Evaluation of Trifluoroethylamine Analogues of Enkephalins. <i>ChemMedChem</i> , 2009, 4, 1416-1420.	3.2	9
119	Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience. <i>Paediatric Anaesthesia</i> , 2014, 24, 625-631.	1.1	9
120	Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model. <i>Pharmacological Research</i> , 2015, 102, 12-21.	7.1	9
121	Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3838-3839.	1.6	9
122	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461.	0.8	9
123	Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). <i>Pharmacological Research</i> , 2016, 111, 247-250.	7.1	9
124	Differential postmortem release of noradrenaline and dopamine from rat brain. <i>Psychopharmacology</i> , 1989, 98, 562-563.	3.1	8
125	Flunarizine attenuates cocaine-induced inhibition of A dopaminergic neurons. <i>Pharmacological Research</i> , 1991, 24, 197-203.	7.1	8
126	Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4715-4719.	2.2	8

#	ARTICLE	IF	CITATIONS
127	The cerebellar GABA α 6 subunit is differentially modulated by chronic ethanol exposure in normal (R100R) and mutated (Q100Q) sNP rats. <i>Brain Research</i> , 2004, 998, 148-154.	2.2	7
128	Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors. <i>European Journal of Pharmacology</i> , 2005, 525, 150-153.	3.5	7
129	Five mutations in the GABA α 6 gene 5' flanking region are associated with a reduced basal and ethanol-induced α 6 upregulation in mutated Sardinian alcohol non-preferring rats. <i>Molecular Brain Research</i> , 2005, 137, 252-257.	2.3	7
130	Antinociceptive activity of Δ^9 -tetrahydrocannabinol non-ionic microemulsions. <i>International Journal of Pharmaceutics</i> , 2010, 393, 239-244.	5.2	7
131	DSM-5 and clinical trials in psychiatry: challenges to come?. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 583-584.	46.4	7
132	Safety of Antiplatelet Agents: Analysis of "Real-World" Data from the Italian National Pharmacovigilance Network. <i>Clinical Drug Investigation</i> , 2017, 37, 1067-1081.	2.2	7
133	Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats. <i>European Journal of Pharmacology</i> , 2009, 620, 36-41.	3.5	6
134	Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 903-911.	1.8	6
135	Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification. <i>ClinicoEconomics and Outcomes Research</i> , 2016, 8, 253.	1.9	6
136	Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the intercritical phase. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 277-281.	0.1	5
137	In vitro evidence for the presence of [3 H]-haloperidol uptake in rat brain. <i>British Journal of Pharmacology</i> , 2003, 138, 188-192.	5.4	5
138	Validated Method to Determine Quetiapine and Norquetiapine in Microsomal Matrix by LC MS ² MS: Implication in Quetiapine Metabolism. <i>Chromatographia</i> , 2014, 77, 75-82.	1.3	5
139	The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. <i>Liver International</i> , 2018, 38, 733-741.	3.9	5
140	Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic. <i>Frontiers in Neurology</i> , 2021, 12, 647995.	2.4	5
141	Oral Cannabinoid Preparations for the Treatment of Chronic Migraine: A Retrospective Study. <i>Pain Medicine</i> , 2022, 23, 396-402.	1.9	5
142	Analysis of CYP2D6 Allele Frequencies and Identification of Novel SNPs and Sequence Variations in Sardinians. <i>ISRN Genetics</i> , 2013, 2013, 1-10.	0.2	5
143	Effect of the amisulpride isomers on rat prolactinemia. <i>European Journal of Pharmacology</i> , 2002, 448, 263-266.	3.5	4
144	Building a virtual archive using brain architecture and Web 3D to deliver neuropsychopharmacology content over the Internet. <i>Computer Methods and Programs in Biomedicine</i> , 2008, 90, 124-136.	4.7	4

#	ARTICLE	IF	CITATIONS
145	Novel approaches to drug-placebo difference calculation: evidence from short-term antidepressant drug-trials. <i>Human Psychopharmacology</i> , 2011, 26, 307-312.	1.5	4
146	Is HCMV Vaccine an Unmet Need? The State of Art of Vaccine Development. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 15-26.	2.1	4
147	Insights Into the Decision Making of Advisory Groups to the Italian Medicines Agency. <i>Therapeutic Innovation and Regulatory Science</i> , 2014, 48, 696-701.	1.6	4
148	Stamina therapies: Let the record stand. <i>Nature</i> , 2014, 506, 434-434.	27.8	4
149	Steps forward in regulatory pathways for acute and chronic heart failure. <i>ESC Heart Failure</i> , 2014, 1, 87-93.	3.1	4
150	Transparency in medical research: Time for a paradigm shift. <i>International Journal of Cardiology</i> , 2015, 186, 259-260.	1.7	4
151	A case-control study of visually evoked postural responses in childhood with primary headaches. <i>Neurological Sciences</i> , 2020, 41, 305-311.	1.9	4
152	Licensing of Generic Medicines, are there Any Challenges Left? A Pharmaceutical Regulatory Perspective. <i>Scientia Pharmaceutica</i> , 2014, 82, 847-856.	2.0	3
153	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. <i>Transplant International</i> , 2017, 30, 1253-1265.	1.6	3
154	Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 738-763.	2.4	3
155	Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues. <i>Schizophrenia Research: Cognition</i> , 2019, 18, 100155.	1.3	3
156	Association of neovascular age-related macular degeneration with month and season of birth in Italy. <i>Aging</i> , 2016, 9, 133-141.	3.1	3
157	A Phase 2a Double-Blind Randomized Trial of REL-1017 (Esmethadone) in Patients with MDD: Analysis of Subscales from the Symptoms of Depression Questionnaire. <i>CNS Spectrums</i> , 2022, 27, 235-235.	1.2	3
158	Rat tyrosine hydroxylase gene polymorphisms. <i>Molecular Brain Research</i> , 1997, 45, 345-348.	2.3	2
159	Evolutionary Psychopharmacology, Mental Disorders, and Ethical Behavior. , 2006, , 97-120.		2
160	Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration. <i>European Journal of Pharmacology</i> , 2008, 598, 16-20.	3.5	2
161	Managed entry agreements. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, O27.	2.7	2
162	European licensing of maintenance treatment in schizophrenia. <i>Lancet, The</i> , 2012, 380, 562-563.	13.7	1

#	ARTICLE	IF	CITATIONS
163	PHP39 The "Weight" of Orphan Drugs in the European Pharmaceutical Policy. A Focus on the Expenditure and the Utilization of Orphan Drugs in Five European Union Countries. Value in Health, 2012, 15, A20.	0.3	1
164	PHP99 How to Deal With Decision Uncertainty? The Italian Experience With Managed Entry Agreements. Value in Health, 2012, 15, A31.	0.3	1
165	The Italian Medicines Agency Experience With Hta Scientific Advice Activities: A Comprehensive Analysis Of Three Years Of National And International Activities. Value in Health, 2014, 17, A27-A28.	0.3	1
166	Generic and biosimilar medicines use and expenditure: A report from the National Observatory on the Use of Medicines (OsMed) of the Italian Medicines Agency (AIFA). Journal of Generic Medicines, 2015, 12, 79-80.	0.2	1
167	New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing. Clinical Drug Investigation, 2021, 41, 529-537.	2.2	1
168	Genotyping of CYP2D6 Polymorphisms by MALDI-TOF Mass Spectrometry in Sardinian People. ISRN Genetics, 2013, 2013, 1-10.	0.2	1
169	Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues. Journal of Clinical Neurophysiology, 2021, 38, 181-185.	1.7	1
170	Sustainable Reimbursements: Towards a Unified Framework for Pricing Drugs with Significant Uncertainties. SSRN Electronic Journal, 0, , .	0.4	1
171	Occlusal splint therapy in patients with MÃ©niÃ©re's disease and temporomandibular joint disorder. Acta Otorhinolaryngologica Italica, 2022, , 1-8.	1.5	1
172	Are changes in the pharmacokinetic (PK) and pharmacodynamic (PD) properties of antipsychotics able to improve efficacy and safety?. Annals of General Psychiatry, 2008, 7, .	2.7	0
173	Contents Vol. 45, 2012. Psychopathology, 2012, 45, I-IV.	1.5	0
174	PIN57 Public Expenditure for Antiretroviral Treatment and Projected Cost-Savings After the Entry of Generic Antiretrovirals in the Italian Pharmaceutical Market. Value in Health, 2012, 15, A247.	0.3	0
175	A focus on real life data concerning antidiabetic drugs: The experience of aifa monitoring registry. Value in Health, 2013, 16, A174.	0.3	0
176	Are we ready? What is missing and what is needed? A regulator's perspective. Orphanet Journal of Rare Diseases, 2014, 9, O25.	2.7	0
177	THE USE OF PLACEBO IN RANDOMIZED CONTROLLED TRIALS IN SCHIZOPHRENIA: A REGULATOR'S VIEW. Schizophrenia Research, 2014, 153, S14.	2.0	0
178	Transparency in medical research: Time for a paradigm shift. Clinical Trials and Regulatory Science in Cardiology, 2015, 2-3, 1-3.	1.0	0
179	Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency). Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 900-902.	1.5	0
180	Eficacia de los antipsicÃ³ticos: relaciÃ³n con la ocupaciÃ³n Ã³ptima de los receptores D2. European Psychiatry (Ed EspaÃ±ola), 2007, 14, 325-334.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder. CNS Spectrums, 2022, 27, 236-236.	1.2	0